Dexfenfluramine in type II diabetes: effect on weight and diabetes control.
To assess the effect of dexfenfluramine on weight loss, diabetic control and blood lipids in type II diabetics over a three-month period. Forty overweight patients in the Diabetic Clinic, Fremantle Hospital, were studied in a double-blind, placebo-controlled trial with a run-in period of one month followed by three months on either dexfenfluramine or placebo. Changes in body weight, and fasting plasma glucose, glycosylated haemoglobin, plasma cholesterol and triglyceride levels. The median change in weight was -3.8 kg in the treatment group (Df) and +0.3 kg in the placebo group (PI) (P = 0.006). The median changes in fasting plasma glucose levels were -1.0 mmol/L (Df) and +0.6 mmol/L (PI) P = 0.010). The median changes in glycosylated haemoglobin levels were -1.4% (Df) and +0.2% (PI) (P = 0.002). The median changes in triglyceride levels were -0.3 mmol/L (Df) and +0.2 mmol/L (PI) (P = 0.017). Cholesterol level did not change significantly. Dexfenfluramine is effective in achieving weight loss and also improved diabetic control in obese type II diabetics over a three-month period.